Robert Sexton

Robert Sexton joined Mustang Bio in October 2022 as Vice President, Program & Alliance Leadership where he is responsible for leading program strategy & governance activities, including CMC, Non-Clinical, Clinical Operations, and Regulatory Affairs, as the R&D Steering Committee Head for Mustang Bio development programs from phase 1 through commercial launch. In addition, as head of alliance management he is responsible for alliance lifecycle management, collaboration, and governance activities of in-licensed products with strategic alliance partners. Robert has more than 20 years of experience in pharmaceutical / biotechnology development and commercialization. Prior to joining Mustang Bio, Robert was Senior Director, Commercial CAR-T Operations at Legend Biotech where he was responsible for developing the market enablement strategy and operating model which facilitated the successful commercial launch of the CAR-T product CARVYKTI™. He also worked for Novartis Pharmaceuticals for 10 years holding roles in clinical operations, patient & specialty services, market access, and cell & gene therapy, most notably, he was a member of the commercial launch team responsible for commercializing, the first commercially approved CAR-T product, Kymriah™.

Robert received his M.S. in Biotechnology from The Johns Hopkins University as well as his MBA in Strategic Management and B.S in Biology from Monmouth University.